Abstract:27 Background: High copayments for oral anti-cancer medications (OAMs) can lead to detrimental financial and clinical outcomes for patients. Most patients insured by Medicare and prescribed an OAM reach the catastrophic phase of spending. 1 Financial assistance programs are increasingly used to defray high out of pocket costs, though their ultimate impact on catastrophic spending has not been well-characterized. This study investigated whether receipt of financial assistance reduced likelihood of catastrophic spending for patients prescribed OAMs. Methods: This retrospective, single-institution, cross-sectional study included all patients prescribed an OAM with a >$0 annual copay at an academic integrated Specialty Pharmacy between 1/1-12/31/2021. Data were sourced through a prescribing-level pharmacy database and through a third-party (Vivor/TailorMed) database. A fixed-effects linear regression model was used to identify the impact of financial assistance (binary predictor) on catastrophic spending (binary outcome), defined as spending above $4430/yr based on the average Medicare Part D threshold from 2022 to enter the catastrophic copayments phase. The model was adjusted for demographic and clinical covariates. Results: 1,186 patients were included in the analysis. Average annual copayment on OAMs was $862.50 (SD = $4,673.47) with 5.6% of patients faced catastrophic spending. 37% of patients received some form of financial assistance. Patients who received assistance had significantly lower annual spending on OAMs overall (ß= -$1236; 95% CI: -$1841-658, p<0.001), but assistance was not associated with less catastrophic spending (OR=0.44; 95% CI: 0.14-1.38, p=0.16). Patients who were male, older, retired, insured by Medicare, and had higher annual household income by census tract were more likely to face catastrophic spending. Those who spoke English as a second language and lived in rural settings were less likely to face catastrophic spending. (Table). Conclusions: Financial assistance programs can decrease overall spending on OAMs but may not address financial burden for patients facing catastrophic level spending. Older adults with incomes too high to qualify for safety net or financial assistance programs may be at uniquely increased risk of catastrophic spending. Future studies should evaluate OAM-induced financial toxicity across diverse delivery systems and develop targeted interventions for patients who spend at catastrophic levels. [Table: see text]

Polypharmacy And Medication Costs At End Of Life Among Commercially Insured Adults Age 65 And Older With Cancer.

Polypharmacy and Potentially Inappropriate Medications in Patients With Advanced Cancer: Prevalence and Associated Factors at the End of Life

Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy

The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment

Potentially inappropriate medication use in older patients with breast and colorectal cancer

Polypharmacy Management in Older Patients

Does financial assistance reduce catastrophic spending for patients prescribed oral anti-cancer medications at an integrated Specialty Pharmacy?

Drug utilization and medication costs at the end of life

Why is end‐of‐life inpatient cost high among cancer patients? A prospective cohort study

Research priorities to address polypharmacy in older adults with cancer

Polypharmacy in primary care: A population-based retrospective cohort study of electronic health records

Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based study

Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study

Medication Costs and Use of Older Americans in Assisted Living Settings: a Nationally Representative Cross-Sectional Study

Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers

Pharmacy Assistance Programs for Oral Anticancer Drugs: A Narrative Review

Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers

Association of polypharmacy with all‐cause mortality and adverse events among elderly colorectal cancer survivors

Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments

Potentially inappropriate medication use based on two deprescribing criteria and related factors in patients with terminal cancer: A cross-sectional study

End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting